LadRx Corp
LadRx Corp (LADX): 12 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.2 months
0% dilution
Lead: Preclinical
12 candidates
N/A
N/A
A transparent, data-derived signal for LadRx Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$50K
Cash
$207K
Quarterly Burn
$553K
Runway
1.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| ladr 10 | Preclinical |
| ladr 7 | Preclinical |
| ladr 8 | Preclinical |
| ladr 9 | Preclinical |
| ladr-10 | Preclinical |
| ladr-7 | Preclinical |
| ladr-8 | Preclinical |
| ladr-9 | Preclinical |
| ladr10 | Preclinical |
| ladr7 | Preclinical |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in LadRx Corp's pipeline?
LadRx Corp (LADX) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LadRx Corp's lead drug candidate?
LadRx Corp's most advanced tracked candidate is ladr 10 (Preclinical) for Solid tumors.
What is LadRx Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LadRx Corp has approximately 1.2 months of cash runway.
What is LadRx Corp's market capitalization?
LadRx Corp's market capitalization is approximately $50K.
Who is the CEO of LadRx Corp?
Stephen Snowdy is the chief executive officer of LadRx Corp (LADX).
Get the full picture on LadRx Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.